{"summary": "ebolaviruses cause severe hemorrhagic fever in primates and respiratory disease in pigs. a total of 2997 EVD cases had been reported, including 2892 confirmed cases with 1998 deaths. since the first outbreak was reported in 1976, five different species of ebolaviruses have been identified and their genomic sequences differ by 35\u201345%. recombinant vesicular stomatitis virus (rVSV)-based and recombinant adenovirus type-5 vector (rAd5)-based EBOV candidate vaccines have been shown to be highly efficacious against EBOV infection and transmission. many side effects, such as fever, acute arthritis, and skin lesions, have been reported. antigens fused with the PA can be anchored effectively and stably to the peptidoglycan of GEM particles. a vaccine approach based on the GEM-PA surface display system eliminates the risk of including recombinant DNA in the vaccine [24,25]. recombinant baculoviruses (rBV-eGP-PA) were harvested at 5 days post transfection. these viruses were defined as the first passage 1 (P1) premaster virus. these viruses were expanded in Sf9 cells to generate virus stocks. a mouse anti-SUDV-GP1 monoclonal antibody was added with 0.3% Evans blue for 1 h at RT. dilution of a fluorescein isothiocyanate-labeled goat anti-mouse IgG antibody was added with 0.3% Evans blue for 1 h at RT. supernatants were mixed with eGP-PA-GEM complexes for 30 min at RT. after binding, the eGP-PA-GEM complexes were collected, washed five times with sterile PBS, and resuspended in PBS to produce SBLP. the target was determined by using a GP-specific antibody for WB. poly (I:C) (Sigma, USA), aluminum hydroxide (Alum; Thermo, USA), and Montanide ISA 201VG (ISA 201VG; Seppic, France) were purchased from the Changchun Institute of Biological Products Co., Ltd. (Changchun, China) and immunized. immunosorbent assays were performed in 96-well polystyrene microtiter plates. dilutions of serum samples were incubated at 37 \u00b0C for 1.5 h. secondary antibodies included HRP-conjugated goat anti-mouse IgG, HRP-conjugated IgG1 and HRP-conjugated IgG2a. the plates were incubated for 48 h at 37 \u00b0C and luciferase activity was measured using Infinite M200. luciferase activity is expressed as the percentage reduction in luciferase activity between the sample wells and control wells. splenocytes were isolated from vaccinated mice at 8 days after second vaccination. then cultured (1 106 cells/mL) with stimulation. eGP-PA fusion gene was amplified by PCR using synthetic oligonucleotide primers. Spodoptera frugiperda (Sf9; Gibco, Grand Island, NY, USA) insect cells were transfected with the recombinant bacmids using Cellfectin II Reagent following the Bac-to-Bac Expression Systems manual (Invitroge, Waltham, MA, USA) rBV-eGP-PA was harvested at 5 days post transfection and defined as the first passage 1 (P1) premaster virus. cells were incubated with a 1:500 dilution of a mouse anti-SUDV-GP1 monoclonal antibody. a 1:200 dilution of a fluorescein isothiocyanate (FITC)-labeled goat anti-mouse IgG antibody was added for 1 h at RT. the cells were observed with a fluorescence microscope after washing. the eGP-PA-GEM complexes were resuspended in PBS and stored at 80 \u00b0C until use. the eGP-PA-GEM complexes were collected, washed five times with sterile PBS. the target was determined by using a GP-specific antibody for WB. mice (six- to eight-weeks-old females) were purchased from the Changchun Institute of Biological Products Co., Ltd. (Changchun, China) and immunized. all research was in compliance with the Welfare and Ethics of Laboratory Animals of China (GB 14925-2001) the assays were performed in 96-well polystyrene microtiter plates. the secondary antibodies included HRP-conjugated goat anti-mouse IgG, HRP-conjugated IgG1 and HRP-conjugated IgG2a, which were incubated at 37 \u00b0C for 1 h. luciferase activity is expressed as the percentage reduction in luciferase activity between the sample wells and control wells. cells were cultured in RPMI 1640 medium (Gibco, San Diego, CA, USA) containing 10% FBS and then stimulated with or without purified SUDV GP antigen (10 g/mL) interleukin 10 (IL-10), IFN-, and TNF-, splenocytes were isolated from vaccinated mice at 8 days after the second vaccination. after 48 h, the supernatants of the stimulated cells were evaluated using murine IL-2, IL-4, IL-10, IFN-, and TNF- ELISA kits. recombinant eGP-PA protein reacted with anti-SUDV-GP1 monoclonal antibodies with good antigenicity. cells were infected with the recombinant baculoviruses in (a) and were mock infected in (b) the surface location of eGP-PA on the GEM particles was also analyzed by WB (Figure 2C) and IFA (Figure 2D) with anti-SUDV-GP1 monoclonal antibody. the results showed that the eGP-PA fusion protein was bound to GEM particles. adjuvant from among ISA 201VG plus poly (I:C), poly (I:C), Alum, and ISA 201VG for SBLP immunization was obtained and analyzed. results showed that all mice immunized with SBLP had significantly stronger SUDV GP-specific IgG and neutralizing antibody titers than mice immunized with PBS or GEM. serum antibody titers were measured with Huh7 cells and 100 TCID50 of pseudotyped virus. serum antibody titers were measured with Huh7 cells and 100 TCID50 of pseudotyped virus. serum samples were collected at 2 weeks after the second immunization. the ratios of IgG2a/IgG1 of SBLP with ISA 201VG plus Poly (I:C) were no significant differences than those of SBLP. the SBLP induced a mixed T-helper 1 (Th1) and T-helper 2 (Th2) immune responses. the levels of cytokine IL-2, IL-4, IL-10, IFN-, and TNF- secreted by splenocytes were significantly higher than those secreted by splenocytes from the mice in the SBLP alone group. the secretion of IFN-, TNF-, and IL-2 was associated with a Th1 profile, whereas the secretion of IL-4 and IL-10 were associated with a Th2 immune response characteristics, we designed a synthetic microconsensus GP based on all strains of SUDV from 1976\u20132012. the strategy for designing the eGP-PA fusion protein, in which eGP is fused to the PA with a linker, is shown in Figure 1B. a cell-free extract containing eGP-PA was mixed with GEM particles. after washing, the particles were subjected to SDS-PAGE analysis. eGP-PA fusion protein was bound to GEM particles. molecular weight marker; Lane 1: GEM particles; Lane 2: recombinant eGP-PA fusion protein bound to GEM particles. IFA analysis of binding of eGP-PA fusion protein with GEM particles. results showed that all mice immunized with SBLP had significantly stronger GP-specific IgG and neutralizing antibody titers than the SBLP alone group. EBOV GP-specific total IgG, IgG1 and IgG2a antibody responses were measured by indirect ELISA with the purified GP protein. data are shown as the mean SD and were analyzed by one-way ANOVA. sera from mice immunized with SBLP with ISA 201VG plus poly (I:C) strongly reacted with the SUDV GP protein after receiving a second immunization, reaching endpoint titers of up to 1:40,960. ELISA results showed that sera from SBLP immunized mice strongly reacted with the SUDV GP protein after receiving a second immunization. the splenocytes were collected from each group 8 days after the second immunization treated and analyzed. the secretion of (A) IFN-, (B) IL-4, and (C) TNF- was measured by using ELISpot kit. splenocytes were prepared from 3 mice per group at 8 days after second vaccination. cell-free supernatants were harvested at 48 h after incubation. data are shown as the mean SD and were analysed using one-way ANOVA. based on nonliving, nongenetically modified L. lactis cells designated GEM particles. chimeric anchor fusion proteins can efficiently, strongly, and selectively bind to GEM particles in culture medium at RT within a short time period. it is easier to obtain purified antigens in a BLP-based vaccine than in a virus-like particle (VLP) vaccine. the importance of a mixed Th1 and Th2 response in mediating protection against lethal EBOV infection has been demonstrated in several reports. ISA 201VG mixed with Poly (I:C) as an adjuvant can effectively improve immune response and protection against lethal EBOV infection. our results showed that SBLP resulted in significant increases in the secretion of these cytokines. these levels also increased in the presence of the ISA 201VG plus poly adjuvant. we successfully constructed an SBLP vaccine displaying the eGP protein antigen."}